For those of you who could not attend the #ENDO2020 sessions this am, due to scheduling or technical challenges, a summary thread #Diabetes#COVID19
We enter the #COVID19 era with an unprecedented set of pharmacological tools that can be used wisely to achieve personalized goals for #T2D
How should we think about the complex interactions between ACE2, DPP4, cardiometabolic inflammation, and the management of #T2D Normally, enhanced ACE2 and reduced DPP4 activity are favorable in PPL with #diabetes
